Kornimate/medical-research-clean huggingface dataset:
rad-67 repeatability and reproducibility

Conditions: Healthy

Summary: the primary objective of this clinical investigation is to evaluate the repeatability and reproducibility of using rad-67 pulse co-oximeter


Eligibility criteria:
inclusion criteria: * at least 18 years of age * weight at least 110 pounds * subjects with the intention of being screened for eligibility to donate blood * the subject has given written informed consent to participate in the study exclusion criteria: * subjects with skin abnormalities at the planned application sites that may interfere with sensor application, per directions-for-use (dfu) or trans-illumination of the site, such as burns, scar tissue, infections, abnormalities, etc. * subjects unwilling to remove nail polish or acrylic nails * subjects with blood cancers such as leukemia * subjects with hemoglobin disorders such as sickle-cell anemia and thalassemia or with known history of infectious diseases such as hiv/aids, syphilis, hepatitis, etc. * subjects with self-disclosed/known pregnancy at the time of enrollment * subjects deemed not suitable for the study at the discretion of the investigator * subjects unlikely to be able to refrain from excessive motion during data collection. excessive motion includes postural changes, making hand gestures, involuntary muscular movements, etc.
efficacy of hyaluronic acid injection in knee osteoarthritis

Conditions: Knee Osteoarthritis; Pain, Joint; Stiffness of Knee, Not Elsewhere Classified; Quality of Life

Summary: the aim of this clinical trial study is to compare the efficacy of hyaluronic injection in patients with symptomatic knee osteoarthritis. the main questions it aims to answer are: * is hyaluronic acid injection improve pain symptom, joint stiffness, and joint function in patients with knee osteoarthritis * is hyaluronic acid injection improve knee performance status and health-related quality of life in patients with knee osteoarthritis participants will be allocated to receive one treatments; either hyaluronic acid or normal saline injections after receiving glucocorticoid injection. researchers will compare the hyaluronic acid with normal saline injection to see if the former show superior effect in terms of pain, joint stiffness, function, as well as health-related quality of life comparing with placebo.

participants who had been diagnosed with knee osteoarthritis according to american college of rheumatology (acr) criteria will be enrolled in this study. after the participants receive the information and consent to participate in this study, they will be examined their affected knee by the co-researchers. ten-milligrams of triamcinolone will be injected intra-articular into knee joint. two-to-four weeks later, the participants will be evaluated for knee pain, stiffness, function and quality of life, as well as knee performance status. participants whose their knee joint absence of effusion will be allocated in to one treatment group; either hyaluronic acid or normal saline. after injection, participants will be scheduled for the follow-up visit in 12 and 24 weeks later. in each follow-up visit, they will be evaluated for joint pain, stiffness, function and quality of life, as well as analgesic use and adverse reaction form treatment.

Eligibility criteria:
inclusion criteria: * all participants who had been diagnosed as knee osteoarthritis according to acr criteria with symptom of knee pain * pain visual analog scare of 4 or higher exclusion criteria: participants who have * cognitive impairment * history of aller to hyaluronic acid or its component * history of knee arthropathy * concomitant with inflammatory arthritis * serious comorbidities or bedridden status * current pregnancy or lactation * currently use of symptomatic slow acting drugs for osteoarthritis (sysadoa) * communication problem

Keywords: hyaluronic acid adjunctive treatment
clinical evaluation of the otosight

Conditions: Otitis Media

Summary: the objective of this study is to evaluate the imaging capabilities and image analysis performance of the otosight middle ear scope in pediatric patients undergoing tympanostomy tube placement for otitis media. in this observational study, results of otosight imaging will not affect patient standard of care.


Eligibility criteria:
inclusion criteria: * children (17 years old or younger) scheduled for tympanostomy tube placement exclusion criteria: * otoscopy contra-indicated or not possible per attending physician's decision

Keywords: ear infection ear tubes myringotomy otitis media tympanostomy
polypill for prevention of cardiovascular disease

Conditions: Cardiovascular Disease

Summary: the purpose of this pilot study is to provide data on the feasibility of conducting a large clinical trial on the polypill (combination of aspirin, angiotensin converting enzyme inhibitor, thiazide diuretic, and statin) for primary prevention of cardiovascular disease (cvd). we hypothesized that a "polypill" comprising the aforementioned four components would significantly reduce the estimated 10-year total cvd risk score with high adherence and no significant increase in adverse effects compared to the standard practice.

this is an open-label, parallel-group, randomized clinical trial comparing a polypill to standard practice (defined as usual care administered to patients with similar conditions). approximately 200 participants will be recruited from three sites in sri lanka: the national hospital of sri lanka, colombo; teaching hospital, kegalle, and teaching hospital, kandy. subsequent to granting written informed consent, patients will undergo screening and baseline evaluation to confirm eligibility, followed by randomization to the polypill or to the standard practice study arm. patients receiving either intervention will return for a total of three monthly clinic visits. physician acceptability will be evaluated through a five-question survey will be mailed to a random sample of physicians from the participating clinical sites and to the council of general practitioners in sri lanka. patient acceptability will be measured in participants who will complete the study as well as those who will be screened but not eligible

Eligibility criteria:
inclusion criteria: * estimated 10-year total cvd risk score \> 20%. the total cvd risk assessment will be based on the recently developed who cvd risk prediction charts * no contraindication for treatment with aspirin, angiotensin converting enzyme inhibitors, low-dose diuretics, or statins * informed consent given exclusion criteria: * patients with established angina pectoris, coronary heart disease, myocardial infarction, transient ischemic attacks, stroke, peripheral vascular disease, coronary revascularization and/or carotid endarterectomy left ventricular hypertrophy (on ecg) or hypertensive retinopathy (grade iii or iv) * patients with secondary hypertension * patients with diabetes type 1 or 2 with overt neuropathy or other significant renal disease. * known renal failure or impairment * atrial fibrillation * alt \> 1.5 times the upper limit of normal * history of liver cirrhosis or hepatitis * history of recent gastrointestinal bleeding (within the last year) * women in child bearing period * history of life-limiting diseases or events * unwillingness to sign informed consent.
safety and clinical activity of thiscart19 in patients with r/r non-hodgkin's b cell lymphoma

Conditions: B-cell Malignancy

Summary: a single arm, open-label, dose-escalation study to evaluate the safety and clinical activity of thiscart19 (allogeneic car-t targeting cd19) in patients with relapsed and/or refractory non-hodgkin's b cell lymphoma (r/r b-nhl).

thiscart19 cell is a non-gene-editing allogeneic car-t cell targeting cd19. this study is designed to evaluate the safety and clinical activity of thiscart19 in patients with cd19 positive, relapsed and/or refractory non-hodgkin's b cell lymphoma (r/r b-nhl).

Eligibility criteria:
inclusion criteria: 1. age 18-70 years old, no gender and race limited; 2. estimated life expectancy \> 12 weeks deemed by investigator； 3. cd19 were positive by histopathology and/or cytology diagnosis； 4. patients with relapsed and/or refractory non-hodgkin's b cell lymphoma (r/r b-nhl)； 5. relevant indicators for disease or assessment within 4 weeks after the last treatment; 6. quality of life score (kps) \>50%； 7. subject has adequate organ function at screening, cardiac ejection fraction ≥ 40%, no evidence of pericardial effusion as determined by an echocardiogram (echo); serum alt/ ast \<3 upper limit of normal (uln); bilirubin\<2.0 mg/dl; serum creatinine ≤1.6 mg/dl and/or bun ≤ 1.5 mg/dl; 8. no remission or relapse after hematopoietic stem cell transplantation or autologous somatic immunotherapy; 9. unsuitable conditions for stem cell transplantation; 10. signed informed consent form (icf). exclusion criteria: 1. women in pregnancy or lactation; 2. in active infection including hepatitis b, hepatitis c, hiv, or other fatal viral and bacterial infection； 3. the absolute count of nonprimary neutrophil \< 0.75×10\^9/l or platelet count \< 50×10\^9/l; 4. abnormal vital signs and failure to cooperate with examination; 5. patients with mental or psychological diseases who cannot cooperate with treatment and efficacy evaluation; 6. highly allergic constitution or history of severe allergy; 7. patients with systemic infection or severe local infection requiring anti-infection treatment; 8. patients with severe autoimmune diseases; 9. presence of any other conditions that are unsuitable for this study as judged by the investigator.
the influential trial- evaluation of national inpatient influenza vaccination program

Conditions: Influenza

Summary: this study plans to learn more about whether a stakeholder-informed, standardized inpatient vaccination program will increase influenza vaccination rates of hospitalized children across us pediatric health systems. the first part of the study is to form a multidisciplinary team of stakeholders, including parents, providers, nurses, pharmacists, informaticists, data analysts and communication experts across three sites in synthesizing a best practice implementation guide for an inpatient influenza vaccination program, which will then be piloted at these three sites.

the overarching goal of this proposal is to determine whether a stakeholder-informed, standardized inpatient influenza vaccination program will increase influenza vaccination rates of hospitalized children across diverse u.s. pediatric health systems. building upon preliminary data and experience with pediatric inpatient influenza vaccine delivery, the investigators will engage a multidisciplinary team of stakeholders in synthesizing a best practice implementation guide for an inpatient influenza vaccination program across three sites. the next phase of the study, using a novel adaptive trial design, will be to implement and test the program across 12 health systems. finally, the investigators will evaluate the program's impact using an established dissemination and implementation framework.

Eligibility criteria:
inclusion criteria: * at least 6 months of age * admitted to an inpatient unit at a participating health system exclusion: - admission to critical care sites or hematology-oncology services exclusion criteria: * at least 6 months of age * admitted to an inpatient unit at a participating health system exclusion: - admission to critical care sites or hematology-oncology services

Keywords: vaccination influenza
race and the use of cardiovascular surgical procedures

Conditions: Cardiovascular Diseases; Heart Diseases; Coronary Disease

Summary: to study the causes of persistent differences in black-white access to tertiary care cardiovascular surgical services (tccs).

background: cardiovascular disease is the leading cause of death among adults in the united states. although not long ago it was widely believed that african-americans had a lower incidence of cardiovascular disease than whites, few now believe this to be the case. however, despite parity in the incidence of cardiovascular disease, there remains a substantial black-white difference in the utilization of tertiary care cardiovascular services (tccs), such as coronary angiography (ca), coronary bypass surgery (cabg) and percutaneous transluminal coronary angioplasty (ptca). race differences have been found with great consistency across studies of varying design. design narrative: the study used a retrospective quasi-experimental population-based epidemiology design to examine the characteristics of the health care provider and the individual patient that account for utilization of tccs. the study had four specific aims: 1) to determine the patient and provider characteristics exclusive of symptomatology that predict black-white differences in referral for coronary angiography; 2) to determine, for patients who are referred for coronary angiography, the patient and provider characteristics that predict black-white differences in receipt of coronary angiography; 3) to determine the patient and provider characteristics exclusive of symptomatology that predict black-white difference in referral for cabg and ptca; 4) to determine, for patients who are referred for cabg or ptca, the patient and provider characteristics that predict black-white differences in receipt of cabg and ptca. the hospital records of every 1996 cardiac discharge from each of three baltimore-area hospitals are reviewed to assign each patient to one of three classes. these classes reflect the medical appropriateness of coronary angiography as estimated by the american college of cardiology and the american heart association. all patients in class 1 (indicating general agreement that coronary angiography is indicated) are interviewed by telephone to ascertain barriers to utilization and other factors that may contribute to the use of services. in addition, a stratified sample of 16 class 1 subjects are interviewed in depth. an estimated 400 referring physicians are surveyed to develop a typology of physician practice patterns. results from patient surveys, physician surveys, and medical record reviews are merged to form the analytical database. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
predictors of adherence to orencia

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to examine the relationship between loading dose and adherence to orencia.


Eligibility criteria:
inclusion criteria: * patients will be identified based on the presence of first infusion claim during study period for orencia * at least 1 medical or facility claim for rheumatoid arthritis at the time of or 6 months prior to index date * patients are required to be continuously enrolled for a minimum pre-index and follow-up period as detailed below * patients with a minimum of 3 infusion claims for orencia * only those patients will be included whose first 3 infusion claims occur within 84 days exclusion criteria: * patients less than 18 years of age at index date. * one or more diagnoses of regional enteritis (including crohn's disease), ulcerative colitis, anal or intestinal fistula, ankylosing spondylitis or other inflammatory spondylopathy, psoriatic arthropathy, or psoriasis any time during the 6-month pre-index period * patients who switch between biologics within their first three infusion claims * restarts, defined as those patients who go back on orencia after a gap of 42 days * patients who are on other biologics at the same time as orencia
a pharmacokinetic study comparing sct400 and rituximab in patients with b-cell non-hodgkin's lymphoma

Conditions: B-cell Non Hodgkin's Lymphoma

Summary: the primary objective of the study is to assess the pharmacokinetic (pk) similarity of sct400 versus rituximab (mabthera®) in patients with cd20+ b-cell non-hodgkin's lymphoma. the secondary objective of the study is to evaluate the pharmacodynamics (pd) and safety of sct400 versus rituximab (mabthera®), as well as the presence of human anti-chimeric antibodies (haca).


Eligibility criteria:
inclusion criteria: 1. aged from 18 to 75 years; 2. having histologically confirmed nhl expressing cd20 antigen; 3. having obtained cr (complete remission) or cru (uncertain complete remisson) after the prior therapy; 4. ecog performance status of 0 to 1 5. expected survival of at least ≥ 3 months; 6. signed an informed consent form which was approved by the institutional review board of the respective medical center . exclusion criteria: 1. had received rituximab or other anti-cd20(+) monoclonal antibody treatment within 1 year before enrollment; 2. having to be at least 4 weeks beyond prior anticancer therapy including corticosteroid, or have not recovered from significant toxicities of prior therapy; 3. participating in other clinical trial within 30 days before enrolment; 4. with serious hematologic dysfunction (white blood cell count of \ 1.5×uln; aspartate amino transferase (ast) and alanine amino transferase (alt) levels of \>2.5 × uln; renal dysfunction (serum creatinine level of \> 1.5×uln ); and international normalized ratio (inr) and partial thromboplastin time or activated partial thromboplastin time (aptt) \> 1.5 × uln (unless on therapeutic coagulation); 5. had received live vaccine within 4 weeks prior to study entry; 6. with other malignancies ; or central nervous system (cns) lymphoma, aids-related lymphoma; or active opportunistic infection, a serious nonmalignant disease; 7. seropositive for hcv antibody, or hiv antibody, or hepatitis b virus surface antigen (hbsag). hbc antibody seropositive, but hbv dna and hbsag negative patients may participle following consultation with a hepatitis expert regarding monitoring and use of hbv antiviral therapy, and provided they agree to receive treatment as indicated, 8. recent major surgery (within 28 days prior to study entry ); 9. with a history of allergic reaction or protein product allergy including murine proteins; 10. pregnant or lactating or not accepted birth control methods including male patients.
clinical characteristics and predictors of adverse outcomes in hfpef

Conditions: Heart Failure With Preserved Ejection Fraction

Summary: heart failure with preserved ejection fraction (hfpef) is a prevalent form of heart failure characterized by impaired left ventricle pressures and diastolic dysfunction. despite its increasing prevalence, effective treatment options for hfpef remain limited, probably due to its heterogenous underlying pathological etiology involving chronic systemic inflammation and metabolic dysregulation. identifying new predictors of poor prognosis is crucial for risk stratification and tailored management.

the prognosis for hfpef is concerning, marked by significant mortality and frequent hospital readmissions. the exact mechanisms underlying hfpef remain unresolved. the clinical syndrome arises from intricate interactions among various risk factors, leading to organ dysfunction and clinical symptoms. common co-morbidities, including atrial fibrillation, diabetes, chronic kidney disease, and obesity, may influence hfpef pathophysiology. recent discussions suggest an inflammatory-metabolic phenotype in hfpef, characterized by heightened inflammatory biomarkers, insulin resistance, hyperglycemia, hyperlipidemia, microvascular endothelial and vascular dysfunction, atherosclerosis, consequently leading to significant myocardial damage. however, there is still a lack of clinical risk predictors associated with metabolic phenotype within hfpef. the aim of this study is to investigate the impact of parameters reflecting the metabolic phenotype, coronary microvascular dysfunction in hfpef and establish their correlation with clinical outcomes. the objective is to identify novel predictors for adverse prognosis in hfpef, potentially serving as targets for drug therapy. this research aims to pave the way for targeted drug interventions in cardiometabolic diseases, offering new avenues for therapeutic approaches.

Eligibility criteria:
inclusion criteria: * patients diagnosed with hfpef; diagnostic criteria for hfpef * presence of heart failure signs/symptoms symptoms * preserved left ventricular ejection fraction (ef) ≥50% * bnp≥35 pg/ml and/or ntprobnp≥125 pg/ml; * at least one additional criteria: presence of cardiac functional and structural abnormalities or diastolic dysfunction. exclusion criteria: * lvef lower than 50% * patients with serious hepatic and renal failure, * non-cardiac causes of dyspnea, such as, asthma * primary pulmonary hypertension. * severe valvular heart disease. * pericardial disease. * recent history of myocardial infarction. * coronary artery disease (stenosis\>50). * reduced contrast opacification (for caimr assessment).

Keywords: risk predictors mortality
evaluation of heart function in breast cancer patients using trastuzumab

Conditions: Cardiotoxicity; Antitumor Drugs; Breast Cancer; Trastuzumab

Summary: by dynamically observing the changes of echocardiogram and biomarkers in breast cancer patients using trastuzumab, evaluate the effect of trastuzumab on cardiac function; determine the sensitivity of echocardiography and biomarker indicators and specificity, explore effective and specific early warning indicators, and provide technical support for the evaluation of the cardiac safety of anti-tumor drugs.

thirty female breast cancer patients using trastuzumab, collected demographic and clinical information of all patients before chemotherapy, performed echocardiography (conventional echocardiography, three-dimensional spot tracking technology), and collected blood samples to detect plasma biology markers (tnt, bnp, gdf-15, topoisomerase), follow-up echocardiography and biomarkers at 1 month, 3 months and 6 months after chemotherapy.

Eligibility criteria:
inclusion criteria: * patients with breast cancer (18-70 years old) * patients who are planning to undergo trastuzumab for the first time exclusion criteria: * organic heart disease such as coronary heart disease, heart valve disease, cardiomyopathy * liver and kidney failure * severe cerebrovascular disease * chronic obstructive pulmonary disease * rheumatic immune system disease * other tumors

Keywords: cardiac safety antitumor drugs breast cancer trastuzumab
a study of cerebral perfusion with tdcs in chronic hypoperfusion

Conditions: Moyamoya Syndrome; Moyamoya Disease; Atheroscleroses, Cerebral

Summary: this study is being done to examine whether transcranial direct current stimulation (tdcs) will increase cerebral blood flow which may provide a clinical benefit such as improving cognitive impairment.


Eligibility criteria:
inclusion criteria: * vasculopathy leading to imaging evidence of hypoperfusion * cognitive impairment exclusion criteria: * pregnancy * contraindication to mri or tdcs including metallic implanted objects. * medical instability or inability to cooperate during the study as assessed by the treating physician to participate in the study.